Angel Lanas
Research Subjects
Angel Lanas has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Eduardo Bajador
2 shared publications- Elena Piazuelo
University Hospital LB, Aragon Health Research Institute (IISAragon), CIBERehd, University of Zaragoza, Zaragoza, Spain
2 shared publications Javier Fuentes
2 shared publicationsJavier Ortego
2 shared publicationsM T Arroyo
2 shared publications- María Teresa Arroyo
Gastroenterology Department, Hospital Clínico Universitario “Lozano Blesa”, IIS Aragón and CIBERehd, Zaragoza, Spain
2 shared publications
Latest Publications
- 30 April 2008
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 67 (5) , AB313
Risk Factors for Missed Advanced Adenomas
- 30 April 2008
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 67 (5) , AB313
Risk Factors for Missed Advanced Adenomas
- 1 February 2007
- Published by Elsevier in Gastroenterology
- Vol. 132 (2) , 490-497
Peptic Ulcer and Bleeding Events Associated With Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial
- 1 February 2007
- Published by Elsevier in Gastroenterology
- Vol. 132 (2) , 490-497
Peptic Ulcer and Bleeding Events Associated With Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial
- 26 August 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics Symposium Series
- Vol. 1 (1) , 16-19
Review article: recommendations for the clinical management of patients taking non‐steroidal anti‐inflammatory drugs – a gastroenterologist's perspective
Summary: There are several risk factors that predispose a patient taking non‐steroidal anti‐inflammatory drugs to an increased risk of upper gastrointestinal bleeding. The most significant are a previous ulcer history and age, but other factors such as non‐steroidal anti‐inflammatory drug dose, concomitant aspirin and Helicobacter pylori infection also play a role.When giving non‐steroidal anti‐inflammatory drug treatment the physician must balance the known benefits in terms of a reduction in pain and inflammation, and in the case of aspirin the cardiovascular benefits, with the potential gastrointestinal risks, which can be fatal. Selective cyclo‐oxygenase‐2 inhibitors have similar efficacy to non‐selective non‐steroidal anti‐inflammatory drugs but a better gastrointestinal safety profile, and were an attractive alternative to traditional non‐steroidal anti‐inflammatory drugs until recent data raised concerns about their cardiovascular safety.It has also been demonstrated that the gastrointestinal benefits of cyclo‐oxygenase‐2 agents are eliminated when they are taken concomitantly with aspirin. A Spanish epidemiological study investigated the relative risk of upper gastrointestinal bleeding with cyclo‐oxygenase‐2 inhibitors and a range of other non‐steroidal anti‐inflammatory drugs. The combination of a non‐steroidal anti‐inflammatory drug plus a proton‐pump inhibitor was found to reduce the risk of gastrointestinal bleeding; the combination of a cyclo‐oxygenase‐2 agent plus a proton‐pump inhibitor further reduced this risk, and was calculated to be a cost‐effective option compared with hospitalization for a gastrointestinal bleeding event.
- 26 August 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics Symposium Series
- Vol. 1 (1) , 16-19
Review article: recommendations for the clinical management of patients taking non‐steroidal anti‐inflammatory drugs – a gastroenterologist's perspective
Summary: There are several risk factors that predispose a patient taking non‐steroidal anti‐inflammatory drugs to an increased risk of upper gastrointestinal bleeding. The most significant are a previous ulcer history and age, but other factors such as non‐steroidal anti‐inflammatory drug dose, concomitant aspirin and Helicobacter pylori infection also play a role.When giving non‐steroidal anti‐inflammatory drug treatment the physician must balance the known benefits in terms of a reduction in pain and inflammation, and in the case of aspirin the cardiovascular benefits, with the potential gastrointestinal risks, which can be fatal. Selective cyclo‐oxygenase‐2 inhibitors have similar efficacy to non‐selective non‐steroidal anti‐inflammatory drugs but a better gastrointestinal safety profile, and were an attractive alternative to traditional non‐steroidal anti‐inflammatory drugs until recent data raised concerns about their cardiovascular safety.It has also been demonstrated that the gastrointestinal benefits of cyclo‐oxygenase‐2 agents are eliminated when they are taken concomitantly with aspirin. A Spanish epidemiological study investigated the relative risk of upper gastrointestinal bleeding with cyclo‐oxygenase‐2 inhibitors and a range of other non‐steroidal anti‐inflammatory drugs. The combination of a non‐steroidal anti‐inflammatory drug plus a proton‐pump inhibitor was found to reduce the risk of gastrointestinal bleeding; the combination of a cyclo‐oxygenase‐2 agent plus a proton‐pump inhibitor further reduced this risk, and was calculated to be a cost‐effective option compared with hospitalization for a gastrointestinal bleeding event.
- Open Access
- 22 December 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (1) , 65-72
Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection
Summary: Background : It is unknown whether the incidence of peptic ulcer changes in areas with a high prevalence of Helicobacter pylori infection.Aim : To determine trends in peptic ulcer complications in a community with a high prevalence of H. pylori infection.Methods : New endoscopic diagnoses of peptic ulcers and their complications from 1985 to 2000 were obtained. H. pylori infection in the adult population, the number of prescriptions for anti‐secretory drugs and non‐steroidal anti‐inflammatory drugs were also evaluated.Results : Although the global prevalence of H. pylori infection remains high in this population (>60%), a 41.4 to 25.4% decrease in the incidence of peptic ulcers and ulcer complications was observed. This was associated with a decrease in the prevalence of H. pylori infection in people under 65 years of age, a 3.5‐fold increase in the number of prescriptions of proton‐pump inhibitors and an increase in the number of prescriptions of non‐steroidal anti‐inflammatory drugs, especially coxibs.Conclusions : In an area with a high prevalence of H. pylori infection, the incidence of peptic ulcer and associated complications is declining rapidly. This was associated with a reduction of the prevalence of H. pylori infection in the young and a widespread use of proton‐pump inhibitors. The increase in the use of non‐steroidal anti‐inflammatory drugs, especially coxibs, has not changed the tendency.
- 22 December 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (1) , 65-72
Open AccessClinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection
Summary: Background : It is unknown whether the incidence of peptic ulcer changes in areas with a high prevalence of Helicobacter pylori infection.Aim : To determine trends in peptic ulcer complications in a community with a high prevalence of H. pylori infection.Methods : New endoscopic diagnoses of peptic ulcers and their complications from 1985 to 2000 were obtained. H. pylori infection in the adult population, the number of prescriptions for anti‐secretory drugs and non‐steroidal anti‐inflammatory drugs were also evaluated.Results : Although the global prevalence of H. pylori infection remains high in this population (>60%), a 41.4 to 25.4% decrease in the incidence of peptic ulcers and ulcer complications was observed. This was associated with a decrease in the prevalence of H. pylori infection in people under 65 years of age, a 3.5‐fold increase in the number of prescriptions of proton‐pump inhibitors and an increase in the number of prescriptions of non‐steroidal anti‐inflammatory drugs, especially coxibs.Conclusions : In an area with a high prevalence of H. pylori infection, the incidence of peptic ulcer and associated complications is declining rapidly. This was associated with a reduction of the prevalence of H. pylori infection in the young and a widespread use of proton‐pump inhibitors. The increase in the use of non‐steroidal anti‐inflammatory drugs, especially coxibs, has not changed the tendency.
- 31 October 2004
- Published by Elsevier in Digestive and Liver Disease
- Vol. 36 (10) , 655-657
Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both
- 31 October 2004
- Published by Elsevier in Digestive and Liver Disease
- Vol. 36 (10) , 655-657
Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both
- 24 May 2004
- Published by Wiley in Helicobacter
- Vol. 9 (3) , 249-254
The Prevalence of Peptic Ulcer not Related to Helicobacter pylori or Non‐Steroidal Anti‐Inflammatory Drug Use is Negligible in Southern Europe
Background and Aim. Helicobacter pylori is the major cause of peptic ulcer disease, but the proportion of H. pylori-negative peptic ulcers seems to be increasing in developed countries. We investigated the frequency of H. pylori-negative peptic ulcer without intake of nonsteroidal anti-inflammatory drugs (NSAIDs) in a Mediterranean European country. Materials and Methods. We prospectively collected consecutive patients with an endoscopically verified active peptic ulcer over 6 months from different areas of Spain. Helicobacter pylori infection was assessed by rapid urease test and histologic examination (corpus and antral biopsies). A 13C-urea breath test was performed if H. pylori was not detected with the invasive test. Patients were considered H. pylori-negative if all three tests were negative. NSAID use was determined by structured data collection. Results. Of 754 consecutive peptic ulcer patients, 16 (2.1%) were H. pylori-negative and had not used NSAIDs before the diagnosis. Of the 472 patients who had duodenal ulcers, 95.7% (n = 452) were H. pylori-positive and only 1.69% (n = 8) were negative for both H. pylori infection and NSAID use; 193 patients had benign gastric ulcers and 87% (n = 168) of them were infected by H. pylori (p < .001 vs. duodenal ulcers). NSAID intake was more frequent in gastric ulcer patients (52.8%) than in duodenal ulcer patients (25.4%; p < .001). Consequently, the frequency of H. pylori-negative gastric ulcer in patients not using NSAID was 4.1% (n = 8). Conclusion. Peptic ulcer disease is still highly associated with H. pylori infection in southern Europe, and only 1.6% of all duodenal ulcers and 4.1% of all gastric ulcers were not associated with either H. pylori infection or NSAID use.
- 24 May 2004
- Published by Wiley in Helicobacter
- Vol. 9 (3) , 249-254
The Prevalence of Peptic Ulcer not Related to Helicobacter pylori or Non‐Steroidal Anti‐Inflammatory Drug Use is Negligible in Southern Europe
Background and Aim. Helicobacter pylori is the major cause of peptic ulcer disease, but the proportion of H. pylori-negative peptic ulcers seems to be increasing in developed countries. We investigated the frequency of H. pylori-negative peptic ulcer without intake of nonsteroidal anti-inflammatory drugs (NSAIDs) in a Mediterranean European country. Materials and Methods. We prospectively collected consecutive patients with an endoscopically verified active peptic ulcer over 6 months from different areas of Spain. Helicobacter pylori infection was assessed by rapid urease test and histologic examination (corpus and antral biopsies). A 13C-urea breath test was performed if H. pylori was not detected with the invasive test. Patients were considered H. pylori-negative if all three tests were negative. NSAID use was determined by structured data collection. Results. Of 754 consecutive peptic ulcer patients, 16 (2.1%) were H. pylori-negative and had not used NSAIDs before the diagnosis. Of the 472 patients who had duodenal ulcers, 95.7% (n = 452) were H. pylori-positive and only 1.69% (n = 8) were negative for both H. pylori infection and NSAID use; 193 patients had benign gastric ulcers and 87% (n = 168) of them were infected by H. pylori (p < .001 vs. duodenal ulcers). NSAID intake was more frequent in gastric ulcer patients (52.8%) than in duodenal ulcer patients (25.4%; p < .001). Consequently, the frequency of H. pylori-negative gastric ulcer in patients not using NSAID was 4.1% (n = 8). Conclusion. Peptic ulcer disease is still highly associated with H. pylori infection in southern Europe, and only 1.6% of all duodenal ulcers and 4.1% of all gastric ulcers were not associated with either H. pylori infection or NSAID use.
- 12 June 2003
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (24) , 2464-2466
Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding
In their report on the use of celecoxib as compared with diclofenac plus omeprazole to reduce the risk of recurrent ulcer bleeding in patients with arthritis, Chan et al. (Dec. 26 issue)1 state that the probability of recurrent bleeding was 4.9 percent in the celecoxib-treated patients (7 of 144) and 6.4 percent in those receiving the combination of diclofenac and omeprazole (9 of 143). These bleeding complications were considered by the adjudication committee to meet the criteria for recurrent ulcer bleeding, which was the primary end point. However, for the purposes of clinical practice, the eight other gastrointestinal events (two in celecoxib-treated patients and six in patients treated with diclofenac plus omeprazole), which were not adjudicated as meeting the criteria for the primary end point, are also clinically relevant and must be taken into account. From this viewpoint, the percentages of patients with bleeding were actually 6.2 percent and 10.5 percent, respectively (per year, 12.6 percent and 21.0 percent, respectively).
- 12 June 2003
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (24) , 2464-2466
Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding
In their report on the use of celecoxib as compared with diclofenac plus omeprazole to reduce the risk of recurrent ulcer bleeding in patients with arthritis, Chan et al. (Dec. 26 issue)1 state that the probability of recurrent bleeding was 4.9 percent in the celecoxib-treated patients (7 of 144) and 6.4 percent in those receiving the combination of diclofenac and omeprazole (9 of 143). These bleeding complications were considered by the adjudication committee to meet the criteria for recurrent ulcer bleeding, which was the primary end point. However, for the purposes of clinical practice, the eight other gastrointestinal events (two in celecoxib-treated patients and six in patients treated with diclofenac plus omeprazole), which were not adjudicated as meeting the criteria for the primary end point, are also clinically relevant and must be taken into account. From this viewpoint, the percentages of patients with bleeding were actually 6.2 percent and 10.5 percent, respectively (per year, 12.6 percent and 21.0 percent, respectively).
- 1 June 2003
- Published by Elsevier in Digestive and Liver Disease
- Vol. 35 (6) , 397-403
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin
- 1 June 2003
- Published by Elsevier in Digestive and Liver Disease
- Vol. 35 (6) , 397-403
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A32-A33
Superoxide anion dismutase prevents the development of adenocarcinoma in a rat model of Barrett's esophagus
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A32-A33
Superoxide anion dismutase prevents the development of adenocarcinoma in a rat model of Barrett's esophagus
- 1 February 2003
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 15 (2) , 173-178
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs
To evaluate the risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drug therapy, common analgesics and individual nonsteroidal anti-inflammatory drugs (NSAIDs). The case group was made up of 1122 consecutive patients admitted with bleeding from a peptic lesion. The 2231 control subjects consisted of 1109 patients hospitalized for other reasons and 1122 outpatients from the same geographical area. The relative risk was calculated by unconditional logistic regression after adjusting for confounding factors. The use of the antiplatelet agent triflusal, and other commonly used cardiovascular drugs, such as beta-receptor blockers and calcium channel blockers, was not associated with increased risk of upper gastrointestinal bleeding. The use of angiotensin-converting enzyme inhibitors reduced the risk of bleeding by 30% (odds ratio 0.7; 95% confidence interval 0.5-0.96). Use of ketorolac (odds ratio 59.4; 95% confidence interval 7.7-454) and piroxicam (odds ratio 19.6; 95% confidence interval 9.3-35.3) carried the highest risk. Use of paracetamol and tramadol was not associated with increased risk of bleeding, but the non-narcotic agent metamizol was associated with a small increase in risk of upper gastrointestinal bleeding (odds ratio 2.6; 95% confidence interval 1.3-5.2). The use of the antiplatelet agent triflusal and other cardiovascular drugs apart from low-dose aspirin was not associated with gastrointestinal bleeding. The use of either NSAIDs or aspirin increased the risk of gastrointestinal bleeding but, among the analgesics, only metamizol induced a small increase in the risk of gastrointestinal bleeding.
- 1 February 2003
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 15 (2) , 173-178
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs
To evaluate the risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drug therapy, common analgesics and individual nonsteroidal anti-inflammatory drugs (NSAIDs). The case group was made up of 1122 consecutive patients admitted with bleeding from a peptic lesion. The 2231 control subjects consisted of 1109 patients hospitalized for other reasons and 1122 outpatients from the same geographical area. The relative risk was calculated by unconditional logistic regression after adjusting for confounding factors. The use of the antiplatelet agent triflusal, and other commonly used cardiovascular drugs, such as beta-receptor blockers and calcium channel blockers, was not associated with increased risk of upper gastrointestinal bleeding. The use of angiotensin-converting enzyme inhibitors reduced the risk of bleeding by 30% (odds ratio 0.7; 95% confidence interval 0.5-0.96). Use of ketorolac (odds ratio 59.4; 95% confidence interval 7.7-454) and piroxicam (odds ratio 19.6; 95% confidence interval 9.3-35.3) carried the highest risk. Use of paracetamol and tramadol was not associated with increased risk of bleeding, but the non-narcotic agent metamizol was associated with a small increase in risk of upper gastrointestinal bleeding (odds ratio 2.6; 95% confidence interval 1.3-5.2). The use of the antiplatelet agent triflusal and other cardiovascular drugs apart from low-dose aspirin was not associated with gastrointestinal bleeding. The use of either NSAIDs or aspirin increased the risk of gastrointestinal bleeding but, among the analgesics, only metamizol induced a small increase in the risk of gastrointestinal bleeding.